IPI-145, an oral, potent PI3K-d,? inhibitor, appears to be well tolerated and has shown initial clinical activity in pts with iNHL, MCL, and CLL.
Infinity released positive phase 1 data on IPI-145, its oral PI3K-inhibitor aimed at treating hematological malignancies.
The results demonstrated that IPI-145 showed clinical activity in B-cell and T-cell malignancies.
Source Abstract from ASH